Lord Abbett & CO. LLC Has $44.47 Million Stock Position in ADMA Biologics Inc $ADMA

Key Points

• Lord Abbett & CO. LLC increased its stake in ADMA Biologics by 1.6%, acquiring an additional 34,346 shares for a total of approximately $44.5 million.
• Raymond James Financial raised its target price for ADMA Biologics from $25.00 to $32.00, while Wall Street Zen downgraded the stock from "hold" to "sell."
• ADMA Biologics reported a quarterly EPS of $0.15, exceeding analysts' estimates, with a 13.8% year-over-year revenue increase of $121.98 million.

Lord Abbett & CO. LLC raised its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 1.6% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,241,623 shares of the biotechnology company's stock after purchasing an additional 34,346 shares during the quarter. Lord Abbett & CO. LLC owned 0.94% of ADMA Biologics worth $44,474,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of ADMA. Skandinaviska Enskilda Banken AB publ acquired a new stake in ADMA Biologics during the 1st quarter valued at approximately $35,000. Tsfg LLC acquired a new position in shares of ADMA Biologics in the 1st quarter worth approximately $51,000. Harvest Fund Management Co. Ltd acquired a new position in shares of ADMA Biologics in the 1st quarter worth approximately $52,000. Farther Finance Advisors LLC grew its position in shares of ADMA Biologics by 1,149.1% in the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 2,505 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new position in shares of ADMA Biologics in the 4th quarter worth approximately $85,000. Institutional investors and hedge funds own 75.68% of the company's stock.

Insider Buying and Selling

In related news, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the sale, the director owned 94,830 shares in the company, valued at $1,987,636.80. This represents a 17.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Steve Elms sold 194,749 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the sale, the director owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. The trade was a 69.04% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 464,621 shares of company stock valued at $9,644,269. Insiders own 3.50% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently commented on ADMA. Raymond James Financial lifted their target price on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. One investment analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $27.67.

ADMA Biologics Stock Down 0.6%

Shares of ADMA stock traded down $0.1060 on Tuesday, reaching $17.5240. 1,515,902 shares of the company's stock traded hands, compared to its average volume of 3,141,622. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The company has a market capitalization of $4.18 billion, a P/E ratio of 20.34 and a beta of 0.38. The business's 50 day moving average price is $18.22 and its two-hundred day moving average price is $18.88.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The business had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. During the same quarter in the previous year, the company posted $0.13 earnings per share. ADMA Biologics's revenue for the quarter was up 13.8% compared to the same quarter last year. On average, equities analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.